PortalPublikationenReinduction of Hedgehog Inhibitors after Checkpoint Inhibiti...

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

Standard

Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients. / DeTemple, Viola K; Hassel, Jessica C; Sachse, Michael M; Grimmelmann, Imke; Leiter, Ulrike; Gebhardt, Christoffer; Eckardt, Julia; Pföhler, Claudia; Angela, Yenny; Hübbe, Hanna; Gutzmer, Ralf.

in: CANCERS, Jahrgang 14, Nr. 21, 5469, 07.11.2022.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

DeTemple, VK, Hassel, JC, Sachse, MM, Grimmelmann, I, Leiter, U, Gebhardt, C, Eckardt, J, Pföhler, C, Angela, Y, Hübbe, H & Gutzmer, R 2022, 'Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients', CANCERS, Jg. 14, Nr. 21, 5469. https://doi.org/10.3390/cancers14215469

APA

DeTemple, V. K., Hassel, J. C., Sachse, M. M., Grimmelmann, I., Leiter, U., Gebhardt, C., Eckardt, J., Pföhler, C., Angela, Y., Hübbe, H., & Gutzmer, R. (2022). Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients. CANCERS, 14(21), [5469]. https://doi.org/10.3390/cancers14215469

Vancouver

DeTemple VK, Hassel JC, Sachse MM, Grimmelmann I, Leiter U, Gebhardt C et al. Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients. CANCERS. 2022 Nov 7;14(21). 5469. https://doi.org/10.3390/cancers14215469

Bibtex

@article{6ff9b7a54552484aaeb6188174349413,
title = "Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients",
abstract = "For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure. Retrospective data analysis was performed with 12 patients with aBCC (locally advanced (n = 8)/metastatic (n = 4)). These patients (male:female 6:6, median age 68 years) initially received HHIs, leading to complete/partial response (66%) or stable disease (33%). Median treatment duration was 20.8 (2-64.5) months until discontinuation due to progression (n = 8), adverse events (n = 3), or patient request (n = 1). Subsequent PD1 inhibition (pembrolizumab 42%, cemiplimab 58%) yielded a partial response (8%), stable disease (33%), or progression (59%). Median treatment duration was 4.1 (0.8-16.3) months until discontinuation due to progression (n = 9), adverse events (n = 1), patient request (n = 1), or missing drug approval (n = 1). HHI reinduction resulted in complete/partial response (33%), stable disease (50%), or progression (17%). Median treatment duration was 3.6 (1-29) months. Response duration in the four responding patients was 2-29+ months. Thus, a subgroup of patients with aBCC responded to reinduction of HHI following PD1i failure. Therefore, this sequential treatment represents a feasible treatment option.",
author = "DeTemple, {Viola K} and Hassel, {Jessica C} and Sachse, {Michael M} and Imke Grimmelmann and Ulrike Leiter and Christoffer Gebhardt and Julia Eckardt and Claudia Pf{\"o}hler and Yenny Angela and Hanna H{\"u}bbe and Ralf Gutzmer",
year = "2022",
month = nov,
day = "7",
doi = "10.3390/cancers14215469",
language = "English",
volume = "14",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "21",

}

RIS

TY - JOUR

T1 - Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients

AU - DeTemple, Viola K

AU - Hassel, Jessica C

AU - Sachse, Michael M

AU - Grimmelmann, Imke

AU - Leiter, Ulrike

AU - Gebhardt, Christoffer

AU - Eckardt, Julia

AU - Pföhler, Claudia

AU - Angela, Yenny

AU - Hübbe, Hanna

AU - Gutzmer, Ralf

PY - 2022/11/7

Y1 - 2022/11/7

N2 - For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure. Retrospective data analysis was performed with 12 patients with aBCC (locally advanced (n = 8)/metastatic (n = 4)). These patients (male:female 6:6, median age 68 years) initially received HHIs, leading to complete/partial response (66%) or stable disease (33%). Median treatment duration was 20.8 (2-64.5) months until discontinuation due to progression (n = 8), adverse events (n = 3), or patient request (n = 1). Subsequent PD1 inhibition (pembrolizumab 42%, cemiplimab 58%) yielded a partial response (8%), stable disease (33%), or progression (59%). Median treatment duration was 4.1 (0.8-16.3) months until discontinuation due to progression (n = 9), adverse events (n = 1), patient request (n = 1), or missing drug approval (n = 1). HHI reinduction resulted in complete/partial response (33%), stable disease (50%), or progression (17%). Median treatment duration was 3.6 (1-29) months. Response duration in the four responding patients was 2-29+ months. Thus, a subgroup of patients with aBCC responded to reinduction of HHI following PD1i failure. Therefore, this sequential treatment represents a feasible treatment option.

AB - For patients with advanced basal cell carcinoma (aBCC) first-line treatment with hedgehog inhibitors (HHIs) and second-line treatment with PD1 inhibitors (PD1i) is available, offering combination and sequencing options. Here, we focus on the efficacy and safety of HHI reinduction after PD1i failure. Retrospective data analysis was performed with 12 patients with aBCC (locally advanced (n = 8)/metastatic (n = 4)). These patients (male:female 6:6, median age 68 years) initially received HHIs, leading to complete/partial response (66%) or stable disease (33%). Median treatment duration was 20.8 (2-64.5) months until discontinuation due to progression (n = 8), adverse events (n = 3), or patient request (n = 1). Subsequent PD1 inhibition (pembrolizumab 42%, cemiplimab 58%) yielded a partial response (8%), stable disease (33%), or progression (59%). Median treatment duration was 4.1 (0.8-16.3) months until discontinuation due to progression (n = 9), adverse events (n = 1), patient request (n = 1), or missing drug approval (n = 1). HHI reinduction resulted in complete/partial response (33%), stable disease (50%), or progression (17%). Median treatment duration was 3.6 (1-29) months. Response duration in the four responding patients was 2-29+ months. Thus, a subgroup of patients with aBCC responded to reinduction of HHI following PD1i failure. Therefore, this sequential treatment represents a feasible treatment option.

U2 - 10.3390/cancers14215469

DO - 10.3390/cancers14215469

M3 - SCORING: Journal article

C2 - 36358887

VL - 14

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 21

M1 - 5469

ER -